India, Feb. 1 -- Qiagen has announced the launch of two syndromic testing panels for its QIAstat-Dx instruments in India, including the Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel, which join the Respiratory SARS-CoV-2 Panel that had been authorised for emergency use in 2020 first time.

The panels have received regulatory approval from the Central Drugs Standard Control Organization (CDSCO), enabling healthcare providers in India to diagnose patients accurately, faster, and easier.

The QIAstat-Dx system is designed for use in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing. Utilising multiplex real-time PCR, it detects and differentiates between mult...